KR102248581B1 - 혈청 샘플 중 항-약물 항체를 검출하기 위한 간섭-억제된 면역분석 - Google Patents

혈청 샘플 중 항-약물 항체를 검출하기 위한 간섭-억제된 면역분석 Download PDF

Info

Publication number
KR102248581B1
KR102248581B1 KR1020157037229A KR20157037229A KR102248581B1 KR 102248581 B1 KR102248581 B1 KR 102248581B1 KR 1020157037229 A KR1020157037229 A KR 1020157037229A KR 20157037229 A KR20157037229 A KR 20157037229A KR 102248581 B1 KR102248581 B1 KR 102248581B1
Authority
KR
South Korea
Prior art keywords
antibody
drug
drug antibody
tcz
sample
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020157037229A
Other languages
English (en)
Korean (ko)
Other versions
KR20160029034A (ko
Inventor
카이-군나르 스투벤라오흐
루돌프 보겔
Original Assignee
에프. 호프만-라 로슈 아게
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 에프. 호프만-라 로슈 아게 filed Critical 에프. 호프만-라 로슈 아게
Publication of KR20160029034A publication Critical patent/KR20160029034A/ko
Application granted granted Critical
Publication of KR102248581B1 publication Critical patent/KR102248581B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/54393—Improving reaction conditions or stability, e.g. by coating or irradiation of surface, by reduction of non-specific binding, by promotion of specific binding
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
KR1020157037229A 2013-07-04 2014-07-01 혈청 샘플 중 항-약물 항체를 검출하기 위한 간섭-억제된 면역분석 Active KR102248581B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP13175091.1 2013-07-04
EP13175091 2013-07-04
PCT/EP2014/063891 WO2015000865A1 (en) 2013-07-04 2014-07-01 Interference-suppressed immunoassay to detect anti-drug antibodies in serum samples

Publications (2)

Publication Number Publication Date
KR20160029034A KR20160029034A (ko) 2016-03-14
KR102248581B1 true KR102248581B1 (ko) 2021-05-06

Family

ID=48703341

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020157037229A Active KR102248581B1 (ko) 2013-07-04 2014-07-01 혈청 샘플 중 항-약물 항체를 검출하기 위한 간섭-억제된 면역분석

Country Status (10)

Country Link
US (2) US10168326B2 (cg-RX-API-DMAC7.html)
EP (1) EP3017303B1 (cg-RX-API-DMAC7.html)
JP (2) JP6563910B2 (cg-RX-API-DMAC7.html)
KR (1) KR102248581B1 (cg-RX-API-DMAC7.html)
CN (1) CN105378480B (cg-RX-API-DMAC7.html)
BR (1) BR112015032960B1 (cg-RX-API-DMAC7.html)
CA (1) CA2913687C (cg-RX-API-DMAC7.html)
MX (1) MX363403B (cg-RX-API-DMAC7.html)
RU (1) RU2674996C2 (cg-RX-API-DMAC7.html)
WO (1) WO2015000865A1 (cg-RX-API-DMAC7.html)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2401040A (en) 2003-04-28 2004-11-03 Chugai Pharmaceutical Co Ltd Method for treating interleukin-6 related diseases
PE20091174A1 (es) 2007-12-27 2009-08-03 Chugai Pharmaceutical Co Ltd Formulacion liquida con contenido de alta concentracion de anticuerpo
SG10201510640QA (en) 2009-10-26 2016-01-28 Hoffmann La Roche Method For The Production Of A Glycosylated Immunoglobulin
KR102116202B1 (ko) 2010-11-08 2020-05-28 제넨테크, 인크. 피하 투여용 항―ｉｌ―6 수용체 항체
EP3667321B1 (en) * 2014-02-11 2022-07-27 Genzyme Corporation Assays for detecting the presence or amount of an anti-drug antibody
EP3391050B1 (en) 2015-12-16 2020-09-16 F. Hoffmann-La Roche AG Three-step acid dissociation enzyme linked immunosorbent (tadelis) assay
EP3592367B1 (en) * 2017-03-07 2025-04-23 Roche Diagnostics GmbH Stable formulations for immune-modulatory macrolides
WO2019030202A1 (en) * 2017-08-08 2019-02-14 F. Hoffmann-La Roche Ag METHOD FOR DETECTION OF ANTI-MEDICATION ANTIBODIES IN A MINI-PORK SAMPLE
WO2019105916A1 (en) * 2017-11-29 2019-06-06 F. Hoffmann-La Roche Ag Target interference suppressed anti-drug antibody assay
MX2021000331A (es) * 2018-07-10 2021-03-25 Regeneron Pharma Metodos para mitigar la interferencia de la diana farmacologica en un inmunoensayo de anticuerpos antifarmaco (ada).
WO2020229378A1 (en) * 2019-05-13 2020-11-19 F. Hoffmann-La Roche Ag Interference-suppressed pharmacokinetic immunoassay
US11913945B2 (en) * 2020-01-02 2024-02-27 Hoffmann-La Roche Inc. Method for determining the amount of a therapeutic antibody in the brain
CN113495141A (zh) * 2020-03-20 2021-10-12 迈克生物股份有限公司 2019新型冠状病毒IgM抗体检测试剂盒
KR20230009502A (ko) * 2020-05-18 2023-01-17 바이오션, 인코포레이티드 Il6r에 결합하는 항체 및 이의 용도
KR102626197B1 (ko) * 2020-11-19 2024-01-18 바디텍메드(주) 항 약물 항체의 수준을 정확하게 정량화하는 방법
JP7062803B1 (ja) 2021-03-31 2022-05-06 積水メディカル株式会社 抗薬物抗体測定方法
CN114047343B (zh) * 2022-01-13 2022-05-31 美迪西普亚医药科技(上海)有限公司 双耐受型抗IgE单抗药物的免疫原性分析试剂盒及其使用方法和应用
WO2024165456A1 (en) * 2023-02-07 2024-08-15 F. Hoffmann-La Roche Ag Method for the detection of anti-aav particle antibodies
WO2024220763A1 (en) * 2023-04-20 2024-10-24 Xentria, Inc. Methods for detecting an anti-drug antibody (ada) against an anti-tnf alpha antibody
CN120761634B (zh) * 2025-09-02 2025-12-05 宁波熙宁检测技术有限公司 一种针对多特异性单克隆抗体药物的ada检测方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009077127A1 (en) 2007-12-15 2009-06-25 F. Hoffmann-La Roche Ag Distinguishing assay
WO2012064627A2 (en) 2010-11-08 2012-05-18 Genentech, Inc. Subcutaneously administered anti-il-6 receptor antibody

Family Cites Families (100)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5238808A (en) 1984-10-31 1993-08-24 Igen, Inc. Luminescent metal chelate labels and means for detection
JPH066054B2 (ja) 1987-10-15 1994-01-26 帝人株式会社 動物細胞の培養方法
US6428979B1 (en) 1988-01-22 2002-08-06 Tadamitsu Kishimoto Receptor protein for human B cell stimulatory factor-2
US5171840A (en) 1988-01-22 1992-12-15 Tadamitsu Kishimoto Receptor protein for human B cell stimulatory factor-2
US5670373A (en) 1988-01-22 1997-09-23 Kishimoto; Tadamitsu Antibody to human interleukin-6 receptor
ZA898290B (en) 1988-11-03 1991-06-26 Igen Inc Electrochemiluminescent assays
US5068088A (en) 1988-11-03 1991-11-26 Igen, Inc. Method and apparatus for conducting electrochemiluminescent measurements
KR0132666B1 (en) 1989-03-14 1998-04-14 Hitachi Kk Method for controlling cultivation conditions for animal cells
DE122009000023I2 (de) 1989-07-20 2010-12-16 Kishimoto Antikörper gegen menschlichen Interleukin-6-Rezeptor
US5122469A (en) 1990-10-03 1992-06-16 Genentech, Inc. Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins
IL100866A (en) 1991-02-06 1995-10-31 Igen Inc Method and apparatus for magnetic microparticulate based luminescence assay including plurality of magnets
ATE181575T1 (de) 1991-04-25 1999-07-15 Chugai Pharmaceutical Co Ltd Rekombinierte humane antikörper gegen den humanen interleukin 6-rezeptor
US5821121A (en) 1991-06-24 1998-10-13 Pacific Biomedical Research, Inc. Hormone-secreting cells maintained in long-term culture
JPH08508875A (ja) 1992-05-01 1996-09-24 帝人株式会社 蛋白分泌細胞の流加回分培養法
EP0567738A3 (en) 1992-05-01 1995-09-06 American Cyanamid Co Controlling perfusion rates in continuous bioreactor culture of animal cells
US5888510A (en) 1993-07-21 1999-03-30 Chugai Seiyaku Kabushiki Kaisha Chronic rheumatoid arthritis therapy containing IL-6 antagonist as effective component
US20030108545A1 (en) 1994-02-10 2003-06-12 Patricia Rockwell Combination methods of inhibiting tumor growth with a vascular endothelial growth factor receptor antagonist
JPH07258252A (ja) 1994-03-16 1995-10-09 Meiji Seika Kaisha Ltd チアゾール化合物およびその塩
US8017121B2 (en) 1994-06-30 2011-09-13 Chugai Seiyaku Kabushika Kaisha Chronic rheumatoid arthritis therapy containing IL-6 antagonist as effective component
JP3630453B2 (ja) 1994-09-30 2005-03-16 中外製薬株式会社 Ｉｌ−６レセプター抗体を有効成分とする未熟型骨髄腫細胞治療剤
CN100350973C (zh) 1994-10-21 2007-11-28 岸本忠三 用于治疗il－6产生所致疾病的药物组合物
US6086874A (en) 1994-12-29 2000-07-11 Chugai Seiyaku Kabushiki Kaisha Antitumor agent effect enhancer containing IL-6 antagonist
WO1996025174A1 (en) 1995-02-13 1996-08-22 Chugai Seiyaku Kabushiki Kaisha Muscle protein decomposition inhibitor containing il-6 receptor antibody
US5614191A (en) 1995-03-15 1997-03-25 The United States Of America As Represented By The Department Of Health And Human Services IL-13 receptor specific chimeric proteins and uses thereof
US5705364A (en) 1995-06-06 1998-01-06 Genentech, Inc. Mammalian cell culture process
CA2238080C (en) 1995-10-23 2012-03-13 Amrad Operations Pty. Ltd. A novel haemopoietin receptor and genetic sequences encoding same
US6087129A (en) 1996-01-19 2000-07-11 Betagene, Inc. Recombinant expression of proteins from secretory cell lines
EP0923941B1 (en) 1996-06-27 2006-05-17 Chugai Seiyaku Kabushiki Kaisha Remedies for myeloma to be used together with nitrogen mustard antitumor agents
WO1998041611A1 (en) 1997-03-20 1998-09-24 Regents Of The University Of Minnesota Process for the continuous culture of cells
WO1998042377A1 (fr) 1997-03-21 1998-10-01 Chugai Seiyaku Kabushiki Kaisha Substances servant a la prevention ou au traitement de maladies liees a la cellule-t sensibilisee contenant comme principe actif des antagonistes de l'il-6
US20020187150A1 (en) 1997-08-15 2002-12-12 Chugai Seiyaku Kabushiki Kaisha Preventive and/or therapeutic agent for systemic lupus erythematosus comprising anti-IL-6 receptor antibody as an active ingredient
ATE383875T1 (de) 1998-03-17 2008-02-15 Chugai Pharmaceutical Co Ltd Prophylaktische oder therapeutische mittel gegen entzündliche erkrankungen des verdauungstraktes enthaltend antagonistische il-6 rezeptor antikörper
US6537782B1 (en) 1998-06-01 2003-03-25 Chugai Seiyaku Kabushiki Kaisha Media for culturing animal cells and process for producing protein by using the same
US6406909B1 (en) 1998-07-10 2002-06-18 Chugai Seiyaku Kabushiki Kaisha Serum-free medium for culturing animal cells
ATE350060T1 (de) 1998-08-24 2007-01-15 Chugai Pharmaceutical Co Ltd Mittel zur vorbeugung oder behandlung von pankreatitis die anti-il-6 receptor antikörper als aktive komponente enthalten
US6284453B1 (en) 1999-09-29 2001-09-04 Steven Anthony Siano Method for controlling fermentation growth and metabolism
AU2001271021A1 (en) 2000-07-05 2002-01-14 Japan As Represented By Secretary Of Osaka University Process for producing glycoprotein
WO2002013859A1 (en) 2000-08-10 2002-02-21 Chugai Seiyaku Kabushiki Kaisha Method of inhibiting antibody-containing solution from coagulating or becoming turbid
JP5485489B2 (ja) 2000-08-11 2014-05-07 中外製薬株式会社 抗体含有安定化製剤
US8703126B2 (en) 2000-10-12 2014-04-22 Genentech, Inc. Reduced-viscosity concentrated protein formulations
EP1324776B2 (en) 2000-10-12 2018-03-21 Genentech, Inc. Reduced-viscosity concentrated protein formulations
US7358067B2 (en) 2000-10-20 2008-04-15 Bioneer A/S Fermentation method for production of heterologous gene products in lactic acid bacteria
EP2351838A1 (en) 2000-10-20 2011-08-03 Chugai Seiyaku Kabushiki Kaisha Crosslinking agonistic antibodies
AU2002210952B2 (en) 2000-10-25 2007-01-11 Chugai Seiyaku Kabushiki Kaisha Preventives or remedies for psoriasis containing as the active ingredient IL-6 antagonist
AU2000279625A1 (en) 2000-10-27 2002-05-15 Chugai Seiyaku Kabushiki Kaisha Blood mmp-3 level-lowering agent containing il-6 antgonist as the active ingredient
WO2002036164A1 (en) 2000-10-27 2002-05-10 Chugai Seiyaku Kabushiki Kaisha Blooe vegf level-lowering agent containing il-6 antagonist as the active ingredient
EP2336149A1 (en) 2001-03-09 2011-06-22 Chugai Seiyaku Kabushiki Kaisha Protein purification method
AU2002256005A1 (en) 2001-03-27 2002-10-08 Smithkline Beecham Corporation Control of glycoforms in igg
UA80091C2 (en) 2001-04-02 2007-08-27 Chugai Pharmaceutical Co Ltd Remedies for infant chronic arthritis-relating diseases and still's disease which contain an interleukin-6 (il-6) antagonist
EP1404813A4 (en) 2001-06-13 2004-11-24 Genentech Inc METHOD FOR CULTIVATING ANIMAL CELLS AND POLYPEPTIDE PRODUCTION IN ANIMAL CELLS
EP3192528A1 (en) 2002-02-14 2017-07-19 Chugai Seiyaku Kabushiki Kaisha Formulation of anti-il6r antibody-containing solutions comprising a sugar as a stabilizer
CA2480059C (en) 2002-03-22 2015-11-24 Amrad Operations Pty. Ltd. Monoclonal antibody against interleukin-13 receptor alpha 1 (il-13r.alpha.1)
JP3822137B2 (ja) 2002-05-20 2006-09-13 中外製薬株式会社 動物細胞培養用培地の添加剤およびそれを用いたタンパク質の製造方法
EP1561756B1 (en) 2002-09-11 2015-12-23 Chugai Seiyaku Kabushiki Kaisha Method of purifying protein
US7550262B2 (en) 2002-11-05 2009-06-23 Mount Sinai School Of Medicine Of New York University PTPN11 (SHP-2) mutations and cancer
DE10255508A1 (de) 2002-11-27 2004-06-17 Forschungszentrum Jülich GmbH Verfahren zur Kultivierung von Zellen zur Produktion von Substanzen
JP4555924B2 (ja) 2003-02-24 2010-10-06 中外製薬株式会社 インターロイキン−６アンタゴニストを含有する脊髄損傷治療剤
US20060239927A1 (en) 2003-03-31 2006-10-26 Kyowa Hakko Kogyo Co., Drug for airway administration
JP4473257B2 (ja) 2003-04-02 2010-06-02 エフ．ホフマン−ラ ロシュ アーゲー インスリン様成長因子ｉ受容体に対する抗体及びその使用
JP4869064B2 (ja) 2003-04-04 2012-02-01 ジェネンテック， インコーポレイテッド 高濃度抗体及びタンパク質製剤
GB2401040A (en) 2003-04-28 2004-11-03 Chugai Pharmaceutical Co Ltd Method for treating interleukin-6 related diseases
DK1623019T4 (en) 2003-05-15 2017-03-27 Wyeth Llc LIMITED GLUCOSE SUPPLY TO ANIMAL CELL CULTURE
AR046071A1 (es) 2003-07-10 2005-11-23 Hoffmann La Roche Anticuerpos contra el receptor i del factor de crecimiento de tipo insulinico y los usos de los mismos
CA2542691C (en) 2003-10-17 2013-09-24 Chugai Seiyaku Kabushiki Kaisha Il-6 antagonist for use as mesothelioma therapeutic agent
AR048210A1 (es) 2003-12-19 2006-04-12 Chugai Pharmaceutical Co Ltd Un agente preventivo para la vasculitis.
US8617550B2 (en) 2003-12-19 2013-12-31 Chugai Seiyaku Kabushiki Kaisha Treatment of vasculitis with IL-6 antagonist
JPWO2005090405A1 (ja) 2004-03-24 2008-04-17 中外製薬株式会社 インターロイキン−６受容体に対するヒト型化抗体のサブタイプ
AR048335A1 (es) 2004-03-24 2006-04-19 Chugai Pharmaceutical Co Ltd Agentes terapeuticos para trastornos del oido interno que contienen un antagonista de il- 6 como un ingrediente activo
TW200902555A (en) 2005-01-03 2009-01-16 Hoffmann La Roche Antibodies against IL-13 receptor alpha 1 and uses thereof
KR20130101161A (ko) 2005-01-05 2013-09-12 추가이 세이야쿠 가부시키가이샤 세포의 배양 방법 및 그 이용
CN101330929B (zh) 2005-10-14 2014-03-05 学校法人福冈大学 胰岛移植中的移植胰岛障碍抑制剂
JP5191235B2 (ja) 2005-10-21 2013-05-08 中外製薬株式会社 心疾患治療剤
AR057582A1 (es) 2005-11-15 2007-12-05 Nat Hospital Organization Agentes para suprimir la induccion de linfocitos t citotoxicos
US20090269335A1 (en) 2005-11-25 2009-10-29 Keio University Therapeutic agent for prostate cancer
US9084777B2 (en) 2005-12-28 2015-07-21 Chugai Seiyaku Kabushiki Kaisha Stabilized antibody-containing formulations
CN104189907A (zh) 2006-01-27 2014-12-10 学校法人庆应义塾 伴有脉络膜血管生成的疾病的治疗药
KR101047207B1 (ko) 2006-03-09 2011-07-06 에프. 호프만-라 로슈 아게 항-약물 항체 분석
US9260516B2 (en) 2006-04-07 2016-02-16 Osaka University Method for promoting muscle regeneration by administering an antibody to the IL-6 receptor
WO2008016134A1 (fr) 2006-08-04 2008-02-07 Norihiro Nishimoto PROCÉDÉ POUR PRÉDIRE LE PRONOSTIC DES PATIENTS ATTEINTS DE POLYARTHRITE rhumatoïde
TWI434855B (zh) 2006-11-21 2014-04-21 Hoffmann La Roche 結合物及其在免疫分析中作為參考標準之用途
JP2010095445A (ja) 2006-12-27 2010-04-30 Tokyo Medical & Dental Univ Ｉｌ−６アンタゴニストを有効成分とする炎症性筋疾患治療剤
KR101508019B1 (ko) 2007-01-23 2015-04-06 고쿠리츠 다이가쿠 호우징 신슈 다이가쿠 만성 거부반응 억제제
US20100129355A1 (en) 2007-07-26 2010-05-27 Osaka University Therapeutic agents for ocular inflammatory disease comprising interleukin 6 receptor inhibitor as active ingredient
MX2010003329A (es) 2007-09-26 2010-04-27 Chugai Pharmaceutical Co Ltd Anticuerpo anti-receptor de il-6.
KR101601986B1 (ko) 2007-10-02 2016-03-17 추가이 세이야쿠 가부시키가이샤 인터류킨 6 수용체 저해제를 유효 성분으로 하는 이식편대숙주병 치료제
CA2701338C (en) 2007-10-15 2018-09-18 Chugai Seiyaku Kabushiki Kaisha Method for production of antibody
PE20091174A1 (es) 2007-12-27 2009-08-03 Chugai Pharmaceutical Co Ltd Formulacion liquida con contenido de alta concentracion de anticuerpo
DE102008005523A1 (de) 2008-01-23 2009-07-30 Robert Bosch Gmbh Kraftstoffinjektor
JP2011512875A (ja) 2008-03-11 2011-04-28 ジェネンテック， インコーポレイテッド 増強されたａｄｃｃ機能を有する抗体
DE102008013899A1 (de) 2008-03-12 2009-09-17 F. Hoffmann-La Roche Ag Verfahren zur Herstellung rekombinanter Proteine bei konstantem Gehalt von pCO2 im Medium
CA2728243C (en) 2008-06-05 2020-03-10 National Cancer Center Il-6 inhibitor for suppressing neuroinvasion in pancreatic cancer
US8323649B2 (en) 2008-11-25 2012-12-04 Alderbio Holdings Llc Antibodies to IL-6 and use thereof
US20120183539A1 (en) 2009-07-31 2012-07-19 Shin Maeda Cancer Metastasis Inhibitor
WO2011019622A1 (en) 2009-08-14 2011-02-17 Genentech, Inc. Cell culture methods to make antibodies with enhanced adcc function
SG10201510640QA (en) 2009-10-26 2016-01-28 Hoffmann La Roche Method For The Production Of A Glycosylated Immunoglobulin
WO2011128096A1 (en) 2010-04-16 2011-10-20 Roche Diagnostics Gmbh Polymorphism markers for predicting response to interleukin-6 receptor-inhibiting monoclonal antibody drug treatment
SI2578231T1 (sl) 2010-05-28 2023-01-31 Chugai Seiyaku Kabushiki Kaisha Okrepljen protitumorski T celični odzivnik
US20130149302A1 (en) 2010-05-28 2013-06-13 Chugai Seiyaku Kabushiki Kaisha Therapeutic agents for pancreatic cancer
CN103119176A (zh) 2010-06-07 2013-05-22 霍夫曼-拉罗奇有限公司 用于预测对白介素-6受体抑制性单克隆抗体药物治疗的响应的基因表达标记
JP6363017B2 (ja) 2011-09-01 2018-07-25 中外製薬株式会社 限外ろ過によって高度に濃縮された抗体を含む組成物を調製するための方法

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009077127A1 (en) 2007-12-15 2009-06-25 F. Hoffmann-La Roche Ag Distinguishing assay
WO2012064627A2 (en) 2010-11-08 2012-05-18 Genentech, Inc. Subcutaneously administered anti-il-6 receptor antibody

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Journal of Immunological Methods, vol.362, pp.101-111 (2010)

Also Published As

Publication number Publication date
JP6761085B2 (ja) 2020-09-23
RU2016101730A (ru) 2017-08-09
JP6563910B2 (ja) 2019-08-21
EP3017303A1 (en) 2016-05-11
MX2015016389A (es) 2016-04-11
US20190094216A1 (en) 2019-03-28
BR112015032960A8 (pt) 2019-12-31
KR20160029034A (ko) 2016-03-14
JP2016530495A (ja) 2016-09-29
MX363403B (es) 2019-03-22
JP2019207246A (ja) 2019-12-05
WO2015000865A1 (en) 2015-01-08
HK1217759A1 (zh) 2017-01-20
CN105378480B (zh) 2018-06-12
CA2913687C (en) 2022-12-13
CN105378480A (zh) 2016-03-02
US20160313322A1 (en) 2016-10-27
BR112015032960B1 (pt) 2021-01-05
US10168326B2 (en) 2019-01-01
RU2674996C2 (ru) 2018-12-14
US10761091B2 (en) 2020-09-01
EP3017303B1 (en) 2018-01-03
CA2913687A1 (en) 2015-01-08
RU2016101730A3 (cg-RX-API-DMAC7.html) 2018-05-15

Similar Documents

Publication Publication Date Title
KR102248581B1 (ko) 혈청 샘플 중 항-약물 항체를 검출하기 위한 간섭-억제된 면역분석
US8530176B2 (en) Distinguishing assay
EP1996943B1 (en) Anti-drug antibody assay
KR102551444B1 (ko) 표적 간섭이 억제된 항-약물 항체 분석
AU2013202747B2 (en) Distinguishing assay
CN113811770A (zh) 抑制干扰的药代动力学免疫测定
HK1217759B (en) Interference-suppressed immunoassay to detect anti-drug antibodies in serum samples
HK1189937B (en) Distinguishing assay

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20151231

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20190617

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20201013

Patent event code: PE09021S01D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20210402

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20210429

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20210429

End annual number: 3

Start annual number: 1

PG1601 Publication of registration
PR1001 Payment of annual fee

Payment date: 20240401

Start annual number: 4

End annual number: 4